Opportunities Preloader

Please Wait.....

Report

Pharmaceutical Contract Development And Manufacturing Organization (CDMO) - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

Market Report I 2025-07-01 I 317 Pages I Mordor Intelligence

Pharmaceutical Contract Development And Manufacturing Organization (CDMO) Market Analysis

The Pharmaceutical contract development and manufacturing organization (CDMO) market size is valued at USD 258.88 billion in 2025 and is projected to reach USD 353.20 billion by 2030, reflecting a 6.41% CAGR. Robust outsourcing demand for complex biologics, the rise of high-potency APIs (HPAPIs), and artificial-intelligence-enabled-enabled process-development platforms underpin this trajectory. Peptide-based GLP-1 therapies, expanding vaccine programs, and sustained investment in digitally connected plants further amplify the need for specialist partners able to absorb capital and regulatory risks. North American innovators continue to anchor high-value biologics and gene-therapy work, while Asia-Pacific cost advantages accelerate capacity expansion. Consolidation-typified by Novo Holdings' USD 16.5 billion purchase of Catalent-signals a decisive shift toward end-to-end providers that combine development, scale-up, and commercial production.

Global Pharmaceutical Contract Development And Manufacturing Organization (CDMO) Market Trends and Insights



Increasing Outsourcing Volume by Large Pharmaceutical Companies

Escalating R&D costs and pipeline complexity drive pharmaceutical majors to off-load non-core manufacturing. Asset-light models free capital for discovery while leveraging CDMO expertise to maintain global supply continuity. Lonza's USD 1.2 billion Vacaville site purchase from Roche underpins this transition, adding 330,000 L of biologics capacity to support blockbuster antibody demand. Outsourcing is most intense for sterile biologics and gene-editing therapies, where regulatory rigor and technical barriers heighten the value of specialist partners.

Surge in Biologics and Complex-Molecule Pipelines

Biological entities now dominate new-drug filings, propelled by antibody-drug conjugates, mRNA vaccines, and cell-based therapeutics. Samsung Biologics secured USD 1.4 billion in new 2024 contracts and is expanding antibody-drug-conjugate suites, illustrating spiraling demand for cGMP biologics supply . Biologics' stringent cold-chain, contamination-control, and analytics requirements solidify a preference for full-scope CDMOs with proven regulatory track records.

Stringent Multi-Region Regulatory Requirements

Divergent dossiers and rolling updates such as the European Medicines Agency's new fee rules raise compliance budgets and prolong variation lead times EMA. CDMOs must operate duplicate quality-management systems and align data-integrity protocols across FDA, EMA, and PMDA audits, challenging smaller entrants.

Other drivers and restraints analyzed in the detailed report include:

Cost and Speed Advantage of Manufacturing in Emerging Markets / Consolidation Toward One-Stop CDMOs / High Capex for Sterile Biologics Suites /

For complete list of drivers and restraints, kindly check the Table Of Contents.

List of Companies Covered in this Report:

Thermo Fisher Scientific Inc. (Patheon) / Lonza Group / Catalent Inc. / Samsung Biologics Co. Ltd. / WuXi AppTec Inc. / Recipharm AB / Jubilant Pharmova Ltd. / Boehringer Ingelheim Group / Pfizer CentreOne / Aenova Holding GmbH / Fujifilm Diosynth Biotechnologies / Baxter BioPharma Solutions / Corden Pharma GmbH / AbbVie Contract Manufacturing / Cambrex Corporation / Syneos Health Inc. / IQVIA Holdings Inc. / Labcorp Drug Development / PAREXEL International Corporation / ICON PLC / Charles River Laboratories International Inc. / Eurofins Scientific SE / SGS Life Science Services SA / CMIC Holdings Co. Ltd / Novotech Pty Ltd / Hangzhou Tigermed Consulting Co. Ltd / Samsung Bioepis Co. Ltd / Tesa Labtec GmbH (TESA SE) / Tapemark / Famar SA /

Additional Benefits:

The market estimate (ME) sheet in Excel format /
3 months of analyst support /

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET LANDSCAPE
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing outsourcing volume by large pharmaceutical companies
4.2.2 Surge in biologics and complex-molecule pipelines
4.2.3 Cost- and speed-advantage of manufacturing in emerging markets
4.2.4 Consolidation toward end-to-end one-stop CDMOs
4.2.5 AI-enabled rapid process-development platforms
4.2.6 GLP-1 and peptide HPAPI capacity build-outs
4.3 Market Restraints
4.3.1 Stringent multi-region regulatory requirements
4.3.2 Capacity-utilization and lead-time risk
4.3.3 High capex for sterile biologics suites
4.3.4 Scarcity of skilled aseptic-manufacturing talent
4.4 Supply-Chain Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.6.1 Dosage-formulation technologies
4.6.2 3D printing applications in OSD
4.6.3 Continuous-manufacturing adoption
4.7 Porter's Five Forces Analysis
4.7.1 Bargaining Power of Suppliers
4.7.2 Bargaining Power of Buyers
4.7.3 Threat of New Entrants
4.7.4 Threat of Substitutes
4.7.5 Competitive Rivalry
4.8 Investment and Funding Landscape

5 MARKET SIZE AND GROWTH FORECASTS (VALUE)
5.1 By Service Type
5.1.1 API Manufacturing
5.1.1.1 Small Molecule
5.1.1.2 Large Molecule
5.1.1.3 High-Potency (HPAPI)
5.1.2 FDF Development and Manufacturing
5.1.2.1 Solid Dose
5.1.2.2 Liquid Dose
5.1.2.3 Injectable Dose
5.1.3 Secondary Packaging
5.2 By Molecule Type
5.2.1 Small Molecule
5.2.2 Large Molecule (Biologics and Biosimilars)
5.2.3 High-Potency APIs
5.3 By Dosage Form
5.3.1 Solid Oral
5.3.2 Sterile Injectables
5.3.3 Topicals and Transdermals
5.3.4 Specialty/Novel (e.g., ODT, Long-acting)
5.4 By Therapeutic Area
5.4.1 Oncology
5.4.2 Metabolic and Endocrine
5.4.3 Cardiovascular
5.4.4 CNS and Psychiatry
5.4.5 Infectious Diseases and Vaccines
5.5 By Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Russia
5.5.2.7 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 India
5.5.3.3 Japan
5.5.3.4 South Korea
5.5.3.5 Australia and New Zealand
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East and Africa
5.5.4.1 Middle East
5.5.4.1.1 United Arab Emirates
5.5.4.1.2 Saudi Arabia
5.5.4.1.3 Turkey
5.5.4.1.4 Rest of Middle East
5.5.4.2 Africa
5.5.4.2.1 South Africa
5.5.4.2.2 Nigeria
5.5.4.2.3 Egypt
5.5.4.2.4 Rest of Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Market Concentration
6.2 Strategic Moves
6.3 Market Share Analysis
6.4 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products and Services, and Recent Developments)
6.4.1 Thermo Fisher Scientific Inc. (Patheon)
6.4.2 Lonza Group
6.4.3 Catalent Inc.
6.4.4 Samsung Biologics Co. Ltd.
6.4.5 WuXi AppTec Inc.
6.4.6 Recipharm AB
6.4.7 Jubilant Pharmova Ltd.
6.4.8 Boehringer Ingelheim Group
6.4.9 Pfizer CentreOne
6.4.10 Aenova Holding GmbH
6.4.11 Fujifilm Diosynth Biotechnologies
6.4.12 Baxter BioPharma Solutions
6.4.13 Corden Pharma GmbH
6.4.14 AbbVie Contract Manufacturing
6.4.15 Cambrex Corporation
6.4.16 Syneos Health Inc.
6.4.17 IQVIA Holdings Inc.
6.4.18 Labcorp Drug Development
6.4.19 PAREXEL International Corporation
6.4.20 ICON PLC
6.4.21 Charles River Laboratories International Inc.
6.4.22 Eurofins Scientific SE
6.4.23 SGS Life Science Services SA
6.4.24 CMIC Holdings Co. Ltd
6.4.25 Novotech Pty Ltd
6.4.26 Hangzhou Tigermed Consulting Co. Ltd
6.4.27 Samsung Bioepis Co. Ltd
6.4.28 Tesa Labtec GmbH (TESA SE)
6.4.29 Tapemark
6.4.30 Famar SA

7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK
7.1 White-space and Unmet-Need Assessment

  • Not Sure / Need Reassuring
    • Confirm Content
      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages
      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives
      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices
      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts
      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies
      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses
      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License
      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats
      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery
      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges
      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card
      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer
      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security
      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security
      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE
  • $4750.00
  • $5250.00
  • $6500.00
  • $8750.00
  • ADD TO BASKET
  • BUY NOW